Do you ever extend adjuvant imatinib for patients with high-risk, localized GIST beyond 3 years?
If so, which patients would you extend treatment?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
The NCCN guidelines appropriately recommend "at least 3 yrs" of adjuvant Imatinib in intermediate to high risk, resected GIST. The decision to continue longer becomes a personalized one based on risk of recurrence, tolerance to Imatinib, coverage, etc. There are scenarios where both, the provider an...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Myo Thant, MD
Answered on
No.
Join for free or sign in to see the full answer